What We're Reading
Industry reads hand-picked by our editors
Jan 22, 2021
-
The Washington Post
Vaccine shortages intensify while some doses sit on shelves, an obstacle to national strategy promised by Biden
-
MedPage Today
New Safety Concern for Migraine Drug?
-
Bloomberg
J&J Vaccine Trial Has Enough Data to Analyze Soon, Fauci Says
-
Future Human
‘Deleted’ DNA Data Just Reappeared on a Popular Database
Jan 21, 2021
-
Reuters
California resumes Moderna COVID-19 vaccine usage after pause
-
STAT
CEO of Mark Cuban's generics company talks drug pricing, manufacturing
-
Associated Press
Fire hits building at Indian producer of COVID-19 vaccines
-
Endpoints News
BIO looks to restructure, laying off staff amid challenge to the trade org’s normal face-to-face style
Jan 20, 2021
-
The Wall Street Journal
Janet Woodcock to Lead FDA on Interim Basis
-
The Washington Post
Elderly begin to drop out of Novavax vaccine trial to get Pfizer and Moderna shots
-
Evaluate Vantage
The pandemic releases its grip on clinical trials
-
Vanity Fair
How Trump's COVID Chaos Drowned the FDA in Junk Science
Jan 19, 2021
Jan 15, 2021
-
The Washington Post
Vaccine reserve was already exhausted when Trump administration vowed to release it, dashing hopes of expanded access
-
FiercePharma
Bristol Myers hematology chief Ahmed's out the door amid CAR-T missteps
-
Bloomberg
Pfizer to Cut Covid Vaccine Deliveries as It Renovates Factory
-
Financial Times
New Bayer drugs will not bridge revenue gap, says pharma head
Jan 14, 2021
-
Pink Sheet
Woodcock To Be Acting US FDA Commissioner, Leaving Agency in Stable, Capable Hands
-
POLITICO
Officials: Trump's promised $200 drug-discount cards won't happen
-
STAT
Former Merck employee arrested for stealing trade secrets on cancer research
-
Healthcare Dive
Talkspace to go public via SPAC in $1.4B deal
Jan 13, 2021
-
The Wall Street Journal
Cancer Death Rate in U.S. Falls by Largest Yearly Amount on Record
-
POLITICO
FDA fights for independence in Trump administration's final days
-
Evaluate Vantage
Merck & Co buys into Kras
-
The New York Times
Johnson & Johnson Expects Covid Vaccine Results Soon but Lags in Production
